Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 201 to 250 of 1521 results for patients and public

  1. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

  2. Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  29 July 2026

  3. Guide to the technology appraisal and highly specialised technologies appeal process (pre June 2023) (PMG18)

    This document concerns the appeal process for the technology appraisal and highly specialised technologies programmes and provides an overview for organisations wishing to lodge an appeal

  4. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

  5. Highly specialised technologies evaluation committee

    Our recommendations on the use of highly specialised technologies are made by an independent advisory committee

  6. Percutaneous endoscopic laser thoracic discectomy (HTG34)

    Evidence-based recommendations on percutaneous endoscopic laser thoracic discectomy. This involves using a laser to heat and destroy some of the inside of the disc and shrink the part that is sticking out.

  7. Extracorporeal shockwave therapy for Peyronie's disease (HTG11)

    Evidence-based recommendations on extracorporeal shockwave therapy for Peyronie's disease. This involves using vibrations caused by sound waves to treat the affected tissue.

  8. Knowledge transfer seminars

    Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing

  9. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  10. Technology appraisal committee A members

    Biographies and registered interests for members of the Technology Appraisal Committee A

  11. Alcohol-use disorders: diagnosis and management of physical complications (CG100)

    This guideline covers care for adults and young people (aged 10 years and older) with physical health problems that are completely or partly caused by an alcohol-use disorder. It aims to improve the health of people with alcohol-use disorders by providing recommendations on managing acute alcohol withdrawal and treating alcohol-related conditions.

  12. NICE Listens

    NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social value issues.

  13. Endoscopic laser foraminoplasty (HTG13)

    Evidence-based recommendations on endoscopic laser foraminoplasty. This involves inserting a laser to remove portions of the disc that have protruded and are narrowing the foramen.

  14. Consultancy service

    Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country

  15. Payments and expenses

    Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

  16. Payments and expenses

    Guide for lay members who we've invited to sit on one of NICE's committees, panels, or groups.

  17. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)

    Evidence-based recommendations on cetuximab (Erbitux) for treating locally advanced squamous cell cancer of the head and neck in adults.

  18. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  19. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  20. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  21. Highly specialised technologies evaluation committee members

    Biographies for each member of the highly specialised technologies evaluation committee.

  22. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  23. Interventional procedures advisory committee members

    Membership details, terms of reference, future meeting dates and past meeting minutes for our interventional procedures advisory committee.

  24. Intramural urethral bulking procedures for stress urinary incontinence in women (HTG86)

    Evidence-based recommendations on intramural urethral bulking procedures for stress urinary incontinence in women. Intramural urethral bulking aims to augment the urethral wall and increase the urethral closure force.

  25. Overweight and obesity management (QS212)

    This quality standard covers prevention, behavioural management, assessment, and treatment of overweight, obesity and central adiposity in children and young people aged over 2 years, and adults. This includes those with established comorbidities, and those with risk factors for other medical conditions. It describes high-quality care in priority areas for improvement.

  26. Metatarsophalangeal joint replacement of the hallux (HTG87)

    Evidence-based recommendations on metatarsophalangeal joint replacement of the hallux. This involves removing the problem joint and replacing it with an artificial one.

  27. Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (HTG12)

    Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.

  28. Subfascial endoscopic perforator vein surgery (HTG32)

    Evidence-based recommendations on subfascial endoscopic perforator vein surgery. This involves cutting and closing off, or heating and sealing, perforator veins so that blood can no longer go through them.

  29. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

    In development Reference number: GID-TA11405 Expected publication date: TBC

  30. Multiple technology appraisal (MTA) process timeline

    These are the main stages in the multiple technology appraisal process used before April 2018.

  31. Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)

    Evidence-based recommendations on sunitinib (Sutent) for untreated advanced or metastatic renal cell carcinoma in adults.

  32. Falls (QS86)

    This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:

  33. Partial left ventriculectomy (the Batista procedure) (HTG19)

    Evidence-based recommendations on partial left ventriculectomy. This involves reducing the size of a part of the heart so it can pump blood more efficiently.

  34. Endometrial cryotherapy for menorrhagia (HTG101)

    Evidence-based recommendations on endometrial cryotherapy for menorrhagia (heavy periods). This involves using cold temperatures to freeze and destroy the lining of the womb.

  35. Cryotherapy for malignant endobronchial obstruction (HTG89)

    Evidence-based recommendations on cryotherapy for malignant endobronchial obstruction. This involves using cold temperatures to destroy the cancer tissue that’s causing a blockage.

  36. About evidence summaries

    Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.

  37. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

  38. Laparoscopic laser myomectomy (HTG9)

    Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.

  39. Healthcare-associated infections: prevention and control in primary and community care (CG139)

    This guideline covers preventing and controlling healthcare-associated infections in children, young people and adults in primary and community care settings. It provides a blueprint for the infection prevention and control precautions that should be applied by everyone involved in delivering NHS care and treatment.

  40. Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

    Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.

  41. Integrated health and social care for people experiencing homelessness (NG214)

    This guideline covers providing integrated health and social care services for people experiencing homelessness. It aims to improve access to and engagement with health and social care, and ensure care is coordinated across different services.

  42. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

  43. Dyspepsia and gastro‑oesophageal reflux disease in adults (QS96)

    This quality standard covers investigating and managing symptoms of dyspepsia (indigestion) and gastro-oesophageal reflux disease (heartburn or reflux) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  44. Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments [ID6212]

    In development Reference number: GID-TA11203 Expected publication date:  08 April 2026

  45. Transilluminated powered phlebectomy for varicose veins (HTG16)

    Evidence-based recommendations on transilluminated powered phlebectomy for varicose veins. This involves using a special light passed underneath the skin to see the veins and removing them by suction.

  46. Research recommendations process and methods guide (PMG45)

    This process and methods guide has been developed to help guidance‑producing centres make research recommendations. It describes a step-by-step approach to identifying uncertainties, formulating research recommendations and research questions, prioritising them and communicating them to the NICE Science Policy and Research (SP&R) team, researchers, and funders

  47. Accessing NHS care and treatment recommended by NICE (ECD4)

    This document contains advice to help you access treatments and care that NICE has recommended

  48. Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]

    In development Reference number: GID-HST10063 Expected publication date: TBC

  49. Intralesional photocoagulation of subcutaneous congenital vascular disorders (HTG56)

    Evidence-based recommendations on intralesional photocoagulation of subcutaneous congenital vascular disorders. This involves inserting a laser fibre into the lesion to deliver the light deep within it.

  50. Low dose rate brachytherapy for localised prostate cancer (HTG81)

    Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.